View profile

FarmaKology Newsletter - Issue #73



May 17 · Issue #73 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+10K Subscribers )!

Today's Startup
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms, and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analytics company driving understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for data-driven drug discovery, announced that they have entered into a strategic partnership to co-market and offer their complementary computational platforms as an integrated drug discovery factory. The companies will initially collaborate on up to 30 pharma and biotechnology drug discovery programs over the next two years.
Landos Biopharma based in Blacksburg, Va., partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets. Omilancor is an oral, gut-restrict LANCL2 agonist being developed for ulcerative colitis (UC), Crohn’s disease (CD), and Eosinophilic Esophagitis (EoE). NX-13 is an oral, gut-restricted compound targeting NLRX1 being developed for UC and CD.
The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.
Eli Lilly and Company said on Monday it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma, a local pharmaceutical manufacturer of generic medicines. Natco will collaborate with Lilly to accelerate the availability of baricitinib in India and improve local treatment options for patients battling Covid-19 patients.
Research & Study
Episode 82: Integrating Sustainability Into Biopharma Strategy Pharm Exec podcast
Job Opportunities
Upcoming Webinar
Advanced Pharmaceutical Manufacturing
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue